Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.61 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803665 | 1.00 | HCRTR1 (0.61) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17812934 | 0.89 | HCRTR2 (0.61) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2291824 | 0.83 | HCRTR2 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL7918180 | 0.83 | HCRTR2 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL7915973 | 0.83 | HCRTR2 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL17803651 | 0.82 | HCRTR2 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL17812933 | 0.81 | HCRTR2 (0.51) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17812927 | 0.81 | HCRTR2 (0.51) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17812946 | 0.79 | HCRTR2 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL17812937 | 0.78 | HCRTR2 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016086358-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089722-A1 | HYDROXYMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320884-A1 | HYDROXMETHYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.